PSORS1
MCID: PSR023
MIFTS: 55

Psoriasis 1 (PSORS1)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Psoriasis 1

MalaCards integrated aliases for Psoriasis 1:

Name: Psoriasis 1 57 11 73 14
Psoriasis Vulgaris 73 16 71 31
Psoriasis 1, Susceptibility to 57 28 5
Psors1 57 11 73
Psoriasis Susceptibility 1 57 12
Psoriasis 73 71
Psoriasis, Susceptibility to, Type 1 38
Pv 73

Characteristics:


Inheritance:

Multifactorial 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
prevalence 1-2% in northern european populations
onset bimodal, ages 16-22 and ages 57-60
inflammatory arthritis may develop in 30% of patients
types of psoriasis include - plaque, guttate, erythrodermic, pustular
environmental triggers include (koebner's phenomenon), sunburn, hiv infection, beta-hemolytic streptococcal infection, certain medications, stress, and alcohol


Classifications:



External Ids:

Disease Ontology 11 DOID:0111286
OMIM® 57 177900
OMIM Phenotypic Series 57 PS177900
MeSH 43 D011565
ICD10 31 L40.0
MedGen 40 C1867449
SNOMED-CT via HPO 69 3723001 89704006 9014002
UMLS 71 C0033860 C0263361

Summaries for Psoriasis 1

OMIM®: 57 Psoriasis (psoriasis vulgaris; PV) is a chronic inflammatory dermatosis that affects approximately 2% of the population. It is characterized by red, scaly skin patches that are usually found on the scalp, elbows, and knees, and may be associated with severe arthritis. The lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. The usual age of onset of psoriasis is between 15 and 30 years, although it can present at any age (summary by Matthews et al., 1996). Generalized pustular psoriasis (GPP) is a life-threatening disease characterized by sudden, repeated episodes of high-grade fever, generalized rash, and disseminated pustules, with hyperleukocytosis and elevated serum levels of C-reactive protein (123260) (summary by Marrakchi et al., 2011). GPP often presents in patients with existing or prior psoriasis vulgaris; however, GPP can develop without a history of PV (Sugiura et al., 2013). Palmoplantar pustulosis and acrodermatitis continua of Hallopeau represent acral forms of pustular psoriasis that have historically been grouped with GPP (summary by Setta-Kaffetzi et al., 2013). Nestle et al. (2009) provided a detailed review of the pathogenesis and genetics of psoriasis. (177900) (Updated 08-Dec-2022)

MalaCards based summary: Psoriasis 1, also known as psoriasis vulgaris, is related to psoriasis 8 and geographic tongue, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 1 is HLA-C (Major Histocompatibility Complex, Class I, C), and among its related pathways/superpathways are Keratinization and Allograft rejection. The drugs Infliximab and Metformin have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and endothelial, and related phenotypes are arthritis and nail pits

UniProtKB/Swiss-Prot: 73 A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

Disease Ontology: 11 A psoriasis that has material basis in variation in HLA-C on chromosome 6p21.33.

Related Diseases for Psoriasis 1

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1541)
# Related Disease Score Top Affiliating Genes
1 psoriasis 8 32.4 CDSN CARD14
2 geographic tongue 31.8 HLA-C CARD14
3 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.1 IL17A CCR6
4 nasopharyngitis 30.7 IL17A CCR6
5 seborrheic dermatitis 30.7 IL17A CCR6
6 impetigo 30.7 CCR6 CARD14
7 psoriasis 14, pustular 30.7 LCE3C LCE3B IL17A CARD14
8 crohn's disease 30.6 IL23R IL17A CCR6
9 dermatophytosis 30.6 IL17A CCR6
10 enthesopathy 30.4 IL17A CCR6
11 inflammatory bowel disease 1 30.4 IL23R IL17A CCR6
12 nail disease 30.4 IL23R IL17A CCR6
13 folliculitis 30.3 IL17A CCR6
14 syphilis 30.2 IL17A HLA-C CCR6
15 spondylitis 30.2 MICA IL23R IL17A HLA-C CCR6
16 histoplasmosis 30.2 MICA CCR6
17 chickenpox 30.2 IL17A CCR6
18 eczema herpeticum 30.2 CDSN CCR6
19 progressive multifocal leukoencephalopathy 30.2 IL17A CCR6
20 ulcerative colitis 30.2 IL23R IL17A CCR6
21 psoriasis 9 30.1 PSORS1C2 CDSN
22 tinea pedis 30.1 IL17A CCR6
23 oral candidiasis 30.1 IL17A CCR6
24 psoriasis 6 30.1 CDSN CARD14
25 psoriasis 5 30.1 CDSN CARD14
26 psoriasis 3 30.1 CDSN CARD14
27 peeling skin syndrome 30.1 PSORS1C2 CDSN
28 anterior uveitis 30.1 IL23R IL17A CCR6
29 celiac disease 1 30.0 IL23R IL17A HLA-C CCR6
30 cellulitis 30.0 IL17A CCR6
31 psoriasis 7 30.0 IL23R CDSN CARD14
32 pityriasis rubra pilaris 30.0 PSORS1C2 IL17A CDSN CARD14
33 blepharitis 30.0 IL17A CCR6
34 leprosy 3 29.9 IL23R IL17A HLA-C CCR6
35 psoriasis 2 29.9 LCE3C LCE3B CARD14
36 skin sarcoidosis 29.9 IL17A CCR6
37 spondyloarthropathy 29.8 IL23R IL17A HLA-C CCR6
38 iritis 29.8 IL17A CCR6
39 spondyloarthropathy 1 29.8 IL23R IL17A CCR6
40 sapho syndrome 29.8 IL17A CCR6
41 behcet syndrome 29.7 IL23R IL17A HLA-C CCR6
42 human cytomegalovirus infection 29.7 IL17A CCR6
43 pneumocystosis 29.7 IL17A CCR6
44 hypopyon 29.7 IL23R IL17A
45 chorioretinitis 29.6 IL17A CCR6
46 arthritis 29.6 MICA IL17A HLA-C CCR6
47 extrapulmonary tuberculosis 29.6 IL17A CCR6
48 autoimmune uveitis 29.6 IL17A CCR6
49 inflammatory bowel disease 17 29.6 IL23R CCR6
50 aortitis 29.5 IL17A CCR6

Graphical network of the top 20 diseases related to Psoriasis 1:



Diseases related to Psoriasis 1

Symptoms & Phenotypes for Psoriasis 1

Human phenotypes related to Psoriasis 1:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 30 HP:0001369
2 nail pits 30 HP:0001803
3 psoriasiform dermatitis 30 HP:0003765
4 onychomadesis 30 HP:0025088

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Skin Nails Hair Nails:
onycholysis
onychomadesis
nail pitting
dystrophic nail changes

Skin Nails Hair Skin:
red, raised, scaly skin patches (elbows, knees, scalp)

Immunology:
hla antigens cw6, b13, b17 associated with psoriasis

Skeletal:
arthritis (large joints, small joint, or central axial skeleton)

Skin Nails Hair Skin Histology:
lymphocytic inflammatory infiltrate
epidermal hyperproliferation
abnormal keratinocyte differentiation
koebner phenomenon

Clinical features from OMIM®:

177900 (Updated 08-Dec-2022)

UMLS symptoms related to Psoriasis 1:


pruritus; exanthema; psoriasiform rash

Drugs & Therapeutics for Psoriasis 1

Drugs for Psoriasis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4 170277-31-3
2
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
3
Tazarotene Approved, Investigational Phase 4 118292-40-3 5381
4
Dapsone Approved, Investigational Phase 4 80-08-0 2955
5
Vedolizumab Approved Phase 4 943609-66-3
6
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
9
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
10
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
13
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
14
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
15
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
16
Desoximetasone Approved Phase 4 382-67-2 5311067
17
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
18
Clocortolone Approved Phase 4 34097-16-0, 4828-27-7 5311052
19
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
21
Ustekinumab Approved, Investigational Phase 4 815610-63-0
22
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
23
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
24
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
25
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
26
Calcipotriol Approved Phase 4 112965-21-6 5288783
27
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
28
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 2791 5311051 32798
29
Adalimumab Approved, Experimental Phase 4 331731-18-1
30
Alefacept Approved, Investigational, Withdrawn Phase 4 222535-22-0
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453
33
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
38
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
39 Antiprotozoal Agents Phase 4
40 Antiparasitic Agents Phase 4
41 Antimalarials Phase 4
42 Trace Elements Phase 4
43 Vasoconstrictor Agents Phase 4
44 Micronutrients Phase 4
45 Calciferol Phase 4
46 Hydrocortisone 17-butyrate 21-propionate Phase 4
47 Pharmaceutical Solutions Phase 4
48 Chelating Agents Phase 4
49 Anti-Bacterial Agents Phase 4
50 Anesthetics Phase 4

Interventional clinical trials:

(show top 50) (show all 1637)
# Name Status NCT ID Phase Drugs
1 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT). Unknown status NCT03307447 Phase 4 Secukinumab
4 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
5 Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study Unknown status NCT03629639 Phase 4 Metformin
6 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
7 Palmoplantar Psoriasis: Evaluating Efficacy and Clinical Photography With Brodalumab in Palmoplantar Psoriasis Unknown status NCT04622033 Phase 4
8 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
9 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
10 Open Label Study, Evaluating Taltz in Combination With Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam in Psoriasis Patients Unknown status NCT04372277 Phase 4 Enstilar
11 An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab Unknown status NCT03827876 Phase 4 Enstilar 0.005%-0.064% Topical Foam
12 A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis. Unknown status NCT04347473 Phase 4 Ilumya Injectable Product
13 Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents. Unknown status NCT04119102 Phase 4 Duobrii
14 Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis After Combination Treatment of Lexette and Sorilux for 2 Weeks Unknown status NCT04571151 Phase 4 LEXETTE 0.05% Topical Foam;Sorilux 0.005 % Topical Foam
15 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
16 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
17 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
18 Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis Unknown status NCT02829424 Phase 4 Methotrexate;Methotrexate Placebo
19 A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis Unknown status NCT03587194 Phase 4 Otezla
20 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
21 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
22 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
23 Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis Unknown status NCT03453190 Phase 4
24 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
25 Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Unknown status NCT03478280 Phase 4 Brodalumab;Placebos
26 Studying the Effect of Methotrexate Alone Versus Methotrexate and Vitamin D on the Cardiovascular Risk of Psoriatic Patients Unknown status NCT03904680 Phase 4 Methotrexate;Vitamin D
27 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
28 The Maintenance Effect of Enstilar Foam in Combination With Otezla Unknown status NCT04555707 Phase 4 Apremilast 30mg;calcipotriene and betamethasone dipropionate
29 Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions Unknown status NCT03629379 Phase 4 Ustekinumab;Vedolizumab
30 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
31 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
32 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
33 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed NCT01707043 Phase 4 Taclonex
34 A Randomized Study Combining Etanercept and Short Courses of Narrow-Band UVB in Patients With Psoriasis Vulgaris Completed NCT00640393 Phase 4 Etanercept
35 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
36 Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris Completed NCT02004574 Phase 4 Calcipotriol/betamethasone dipropionate gel
37 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
38 Different Treatment Regimens of Calcipotriol Cream and Combination (Calcipotriol/Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris Completed NCT00216892 Phase 4 Calcipotriol, (calcipotriol + betamethasone)
39 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
40 A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Completed NCT03331835 Phase 4 Fumaric acid esters
41 An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis Completed NCT03022617 Phase 4 Apremilast
42 A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis Completed NCT02125279 Phase 4 Calcitriol
43 Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis Completed NCT03348462 Phase 4 ethosomal preparation of anthralin;liposomal preparation of anthralin
44 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
45 Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin Completed NCT00723437 Phase 4 acitretin
46 Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment Completed NCT02655705 Phase 4 Cyclosporine A;Methotrexate
47 Randomised, Open-label Preliminary Study to Assess the Effects of 2 Regimens of Etanercept on Nail and Skin Symptoms in Patients With Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
48 A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis Completed NCT03942042 Phase 4 Ixekizumab
49 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
50 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept

Search NIH Clinical Center for Psoriasis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Genetic Tests for Psoriasis 1

Genetic tests related to Psoriasis 1:

# Genetic test Affiliating Genes
1 Psoriasis 1, Susceptibility to 28 HLA-C

Anatomical Context for Psoriasis 1

Organs/tissues related to Psoriasis 1:

MalaCards : Skin, Liver, Endothelial, T Cells, Neutrophil, Monocytes, Pituitary

Publications for Psoriasis 1

Articles related to Psoriasis 1:

(show top 50) (show all 30707)
# Title Authors PMID Year
1
Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. 62 57 5
16642438 2006
2
Myeloperoxidase Modulates Inflammation in Generalized Pustular Psoriasis and Additional Rare Pustular Skin Diseases. 62 57
32758447 2020
3
Clinical improvement in psoriasis with specific targeting of interleukin-23. 62 57
25754330 2015
4
The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. 62 57
23698098 2013
5
Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. 62 57
23303454 2013
6
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. 62 57
22521419 2012
7
Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. 62 57
21848462 2011
8
Cutting edge: A critical functional role for IL-23 in psoriasis. 62 57
20956338 2010
9
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. 62 57
20953190 2010
10
Characterisation of psoriasis susceptibility locus 6 (PSORS6) in patients with early onset psoriasis and evidence for interaction with PSORS1. 62 57
19525279 2009
11
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. 62 57
19684581 2009
12
Psoriasis. 62 57
19641206 2009
13
Further genetic evidence for three psoriasis-risk genes: ADAM33, CDKAL1, and PTPN22. 62 57
18923449 2009
14
Psoriasis is associated with increased beta-defensin genomic copy number. 62 57
18059266 2008
15
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. 62 57
17603494 2007
16
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. 62 57
17287478 2007
17
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). 62 57
16380428 2005
18
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. 62 57
16235096 2005
19
Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. 62 57
16163348 2005
20
Mapping of the major psoriasis-susceptibility locus (PSORS1) in a 70-Kb interval around the corneodesmosin gene (CDSN). 62 57
15529278 2005
21
Transgenic mouse models support HCR as an effector gene in the PSORS1 locus. 62 57
15190014 2004
22
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. 62 57
14981113 2004
23
The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. 62 57
12851855 2003
24
Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. 62 57
12648227 2003
25
Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. 62 57
12588373 2003
26
Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. 62 57
12461524 2003
27
Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese hans. 62 57
12485440 2002
28
Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. 62 57
12148091 2002
29
Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. 62 57
11875053 2002
30
HLA-Cw6-positive and HLA-Cw6-negative patients with Psoriasis vulgaris have distinct clinical features. 62 57
11841557 2002
31
Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. 62 57
11851889 2002
32
Interleukin-10 promoter polymorphism in psoriasis. 62 57
11407990 2001
33
Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. 62 57
11556968 2001
34
The HCR gene on 6p21 is unlikely to be a psoriasis susceptibility gene. 62 57
11348465 2001
35
Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. 62 57
11134234 2001
36
HLA-C and guttate psoriasis. 62 57
11122018 2000
37
The OTF3 gene polymorphism confers susceptibility to psoriasis independent of the association of HLA-Cw*0602. 62 57
11069619 2000
38
A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. 62 57
10888604 2000
39
Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. 62 57
10801386 2000
40
Evidence for interaction between psoriasis-susceptibility loci on chromosomes 6p21 and 1q21. 62 57
10577939 1999
41
Association analysis using refined microsatellite markers localizes a susceptibility locus for psoriasis vulgaris within a 111 kb segment telomeric to the HLA-C gene. 62 57
10545595 1999
42
Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3. 62 57
10469328 1999
43
Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. 62 57
10332047 1999
44
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. 62 57
10225967 1999
45
Psoriasis linkage in the HLA region. 62 57
10053024 1999
46
Analysis of three suggested psoriasis susceptibility loci in a large Swedish set of families: confirmation of linkage to chromosome 6p (HLA region), and to 17q, but not to 4q. 62 57
9858851 1999
47
Vitamin D receptor polymorphism is associated with psoriasis. 62 57
9886274 1999
48
Familial psoriasis and HLA-B: unambiguous support for linkage in 97 published families. 62 57
9694251 1998
49
Linkage analysis of human leukocyte antigen (HLA) markers in familial psoriasis: strong disequilibrium effects provide evidence for a major determinant in the HLA-B/-C region. 62 57
9634500 1998
50
Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. 62 57
9620305 1998

Variations for Psoriasis 1

ClinVar genetic disease variations for Psoriasis 1:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-C HLA-C, HLA-Cw6 VAR Risk Factor
14906 GRCh37:
GRCh38:

Expression for Psoriasis 1

Search GEO for disease gene expression data for Psoriasis 1.

Pathways for Psoriasis 1

Pathways related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.99 LCE3C LCE3B LCE2B CDSN
2 11.1 MICA IL17A HLA-C
3 10.7 IL23R IL17A CCR6

GO Terms for Psoriasis 1

Biological processes related to Psoriasis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to Gram-positive bacterium GO:0050830 9.73 LCE3C LCE3B IL17A
2 defense response to Gram-negative bacterium GO:0050829 9.56 LCE3C LCE3B IL23R IL17A
3 epidermis development GO:0008544 9.55 LCE3C LCE3B LCE2B CDSN
4 keratinization GO:0031424 9.23 SPRR4 LCE3C LCE3B LCE2B

Sources for Psoriasis 1

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....